Physician profile
Benjamin P Young
NPI 1306865704
$14,488.32
in general payments reported to CMS, 2019-2025
26 companies · $7,269 in 2025
The $7,269 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,091 · 2020: $1,682 · 2021: $957 · 2022: $1,720 · 2023: $1,111 · 2024: $658 · 2025: $7,269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,321 · Education: $2,500 · Consulting Fee: $1,300 · Food and Beverage: $917.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,321.05 |
| Education | $2,500.00 |
| Consulting Fee | $1,300.00 |
| Food and Beverage | $916.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,341.09 | 2022-2025 | |
| Covidien LP | $1,683.45 | 2019-2020 | |
| Ethicon INC. | $1,592.82 | 2021-2025 | Monarch Platform |
| Medical Device Business Services, INC. | $1,501.78 | 2025 | Monarch |
| Visionair Solutions, LLC | $1,300.00 | 2025 | Visionair Patient Specific Airway Stent |
| Noah Medical Corporation | $852.97 | 2023-2025 | Galaxy |
| Pulmonx Corporation | $559.28 | 2019-2022 | |
| Olympus America INC. | $550.71 | 2024 | |
| Pinnacle Biologics, INC | $232.93 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $96.77 | 2019-2023 | Breztri |
| Insmed, INC. | $90.50 | 2020 | |
| Abbott Laboratories | $81.35 | 2023 | Epic |
| Boston Scientific Corporation | $70.18 | 2020 | |
| Merck Sharp & Dohme LLC | $66.90 | 2019-2023 | Recarbrio, Zerbaxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.64 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $56.99 | 2022-2023 | Rebyota |
| Imbio INC. | $56.50 | 2023 | Imbio Lung Density Analysis |
| Mylan Specialty L.P. | $53.90 | 2019-2023 | Yupelri |
| Davol INC. | $48.21 | 2020 | |
| Glaxosmithkline, LLC. | $47.33 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $34.49 | 2019 | |
| Body Vision Medical INC. | $33.79 | 2023 | Lungvision |
| Harmony Biosciences LLC | $28.74 | 2023 | Wakix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.26 | 2022 | |
| Genentech USA, INC. | $15.03 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $11.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.